15 results about "Gonadal hormones" patented technology

The invention provides a polypeptide with an ovary maturation promoting effect and application of the polypeptide in parturition induction of pomfret. The amino acid sequence of the polypeptide is SEQ ID NO: 1. The polypeptide provided by the invention is derived from the GnRH2 gene of the pomfret, and in-vivo experiments prove that the polypeptide can efficiently stimulate the pituitary of the pomfret to secrete gonadotropin, so that the spawning induction time is remarkably shortened, and the spawning rate and the relative spawning amount of parent fish are increased. The polypeptide is strong in species specificity and good in physiological compatibility, does not generate an antibody, avoids side effects of traditional heterologous hormones, is safe and effective, and has a huge potential of being developed into a special spawning induction agent for the pomfret.

The invention discloses a timed insemination method for improving the pregnancy rate and the lambing rate of sheep, and belongs to the technical field of livestock breeding. In order to solve the problem that the pregnancy rate of existing sheep is unstable during regular insemination, the method comprises the steps that a progesterone sponge suppository is embedded in the vagina of a healthy and reproductive ewe on the 0th day, and meanwhile 25 g of luteinizing hormone is injected in an intramuscular mode to release hormone A3; removing the thrombus on the 12th day, and performing intramuscular injection of 400IU of pregnant mare serum gonadotropin at the same time; and after the suppository is removed, insemination is carried out on the cervix orifice of the ewe with ram semen diluted at the ratio of 1: (5-8) in 52h and 64h respectively. According to the method, ovarian activities of the ewes are regulated and controlled, the estrus synchronism and the ovulation rate are improved, tests show that the pregnancy rate reaches 81.6%, the lambing rate is 1.14, compared with a conventional method, the pregnancy rate and the lambing rate of the sheep are remarkably improved, and development of the sheep industry is promoted.

The present invention relates to the field of mammalian reproduction and use of a GnRH antagonist in the regulation and control of estrus of a mammal. The GnRH antagonist can inhibit oestrus for a longer time with less frequent use, and can be used for estrus synchronization and batch reproduction of livestock husbandry animals or regulation and control of estrus of pets.

Provided are a crystal form of a gonadotropin releasing hormone antagonist, a preparation method therefor, and use thereof. A crystal form C and a crystal form D have high purity, good illumination stability, high temperature stability, and high humidity stability, and have good solubility and low hygroscopicity; the saturation solubility of the crystal form C and the crystal form D is 101.75 μg / ml and 87.21 μg / ml, respectively; when the relative humidity is increased from 0 to 50% RH, the hygroscopy gain of the crystal form C and the crystal form D is not greater than 1.76% and 0.73%, respectively; and when the relative humidity is increased from 0 to 90% RH, the hygroscopy gain of the crystal form C and the crystal form D is not greater than 3.43% and 1.61%, respectively. Therefore, the control of a production condition is facilitated, the preparation process is simple, the quality is stable, and large-scale industrial production is easy.

The invention provides a preparation device and a preparation method for cattle superovulation hormone, and relates to the technical field of gonadotropin preparation, the preparation device comprises a mounting rack, two rotating racks are fixed on the vertical surface of the mounting rack, a centrifugal assembly is arranged between the two rotating racks, the centrifugal assembly comprises a central disc, and the central disc is fixed on the mounting rack. The centrifugal assembly is composed of two centrifugal cylinders which do not interfere with each other, the centrifugal cylinder at the upper end is used for centrifugal rotation, the centrifugal cylinder at the lower end is used for centrifugal rotation, the centrifugal cylinder at the upper end is used for centrifugal rotation, and the centrifugal cylinder at the lower end is used for centrifugal rotation. The centrifugal cylinder at the lower end is used for standing and layering, supernatant is conveniently taken out, meanwhile, the cylindrical protective film arranged in the centrifugal cylinder can prevent residual liquid from being left in the centrifugal cylinder, sediment is conveniently discharged, and the centrifugal cylinder can be continuously used by replacing the cylindrical protective film.

The present invention relates to the field of mammalian reproduction. Disclosed is use of a GnRH antagonist in the regulation and control of estrus of a mammal. The GnRH antagonist can inhibit oestrus for a longer time with less frequent use, and can be used for estrus synchronization and batch reproduction of livestock husbandry animals or regulation and control of estrus of pets.

A messenger ribonucleic acid (mRNA) vaccine for Bandavirus dabieense (DBV) and a preparation method thereof are provided. The provided mRNA molecule is an mRNA obtained by cloning an optimized DBV glycoprotein gonadotropins (Gn) sequence into a pGEM-3Zf (+) mRNA vaccine vector, linearizing a plasmid via enzyme digestion, and capping and adding a poly(A) tail through an in vitro transcription enzyme method. The mRNA is encapsulated using a lipid nanoparticle delivery system to obtain the mRNA vaccine.

Described are lipidated GnRH analogues, wherein the GnRH analogues are lipidated at one or more of amino acid positions, such as amino acid position 1, 5, 6 and / or 8 of a GnRH analogue peptide backbone. Also described are methods of making the lipidated compounds, pharmaceutical compositions comprising the lipidated compounds, and their use in methods of treatment.

This invention belongs to the field of assisted reproductive technology, specifically relating to a controlled ovarian stimulation method and supporting drug composition for in vitro fertilization-embryo transfer. The core of this invention does not use GnRH agonists or antagonists throughout the entire process, employing clomiphene combined with individualized, adequate doses of postmenopausal gonadotropins to induce ovulation. A combined packaged drug composition of these two drugs is provided to suit the needs of individuals with high, normal, and low ovarian responses. This method achieves an early ovulation rate of less than 0.2%, an incidence of ovarian hyperstimulation syndrome of less than 1%, and reduces the cost of ovulation induction drugs per cycle by more than 80% compared to existing mainstream methods. It also boasts a stable clinical pregnancy rate and can be widely applied to assisted reproductive ovulation induction treatment for various infertile patients, significantly reducing their economic and time burden.

This invention relates to the field of animal reproductive regulation technology, and discloses a twinning regulator for sika deer males that synchronize estrus and its application method. The regulator is a homogeneous and transparent sol system prepared from trehalose, pituitary follicle-stimulating hormone (FSH), medium- and low molecular weight sodium hyaluronate, low molecular weight dextran sulfate, zinc gluconate, and physiological saline. This invention utilizes sodium hyaluronate of a specific molecular weight and dextran sulfate to construct a polysaccharide sol network, combined with the cross-linking effect of zinc gluconate and the physicochemical stabilizing effect of trehalose, to encapsulate and slowly release FSH. The application method includes implanting and removing a vaginal silicone plug, combined with the injection of pregnant mare serum gonadotropin (PMSG) and the regulator, followed by natural mating. This invention prolongs the half-life of exogenous hormones in the animal, avoids drastic fluctuations in blood drug concentration, and improves the stability of twinning rates in sika deer.

The invention belongs to the field of veterinary drugs, and discloses a novel veterinary drug for promoting ovulation and pregnancy rate of female livestock and a preparation method thereof. The veterinary drug is prepared from gonadorelin, human chorionic gonadotropin, pregnant mare serum gonadotropin, vitamin A palmitate, vitamin E acetate, sodium selenite, zinc sulfate heptahydrate, herba epimedii powder, radix angelicae sinensis powder and corn starch. The preparation method comprises the key steps of performing cryogenic crushing on the composite traditional Chinese medicine powder, adding the fat-soluble vitamins through melt spraying, performing gradient mixing on hormones, performing vibrated fluidized bed drying and the like. Through the synergistic effect of hormones, vitamins, trace elements and traditional Chinese medicines, the problems of single ovulation promoting effect, limited pregnancy rate improvement and poor preparation stability in the prior art are effectively solved. Tests prove that the veterinary drug can remarkably improve the ovulation rate and pregnancy rate of cows, sows and ewes, and the veterinary drug is good in product uniformity, high in stability and convenient to use and has good clinical application prospects.

The application belongs to the field of medicine, and particularly relates to application of new litse base in treatment of polycystic ovary syndrome. For a rat PCOS model caused by dehydroepiandrosterone, the new litse base can improve the serum estradiol (E2) level, reduce the follicle stimulating hormone (FSH), luteinizing hormone (LH) and testosterone hormone levels, has a significant treatment effect on PCOS, and provides a new drug selection for subsequent treatment of PCOS.

Described herein are radiotherapeutics that target tumor cells expressing the gonadotropin-releasing hormone receptor (GnRHR) and their use in the treatment and / or diagnosis of cancer.

The present application relates to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition and preparation and application thereof. The composition provided by the present application comprises Ramulus cinnamomi, Poria cocos, Cortex moutan, Semen persicae, Radix paeoniae alba, Radix rubiae, Cornus officinalis, and Rhizoma sparganii. The composition can obviously reduce the prostate index and prostate epithelial thickness of a benign prostatic hyperplasia model rat, and relieve interstitial edema. The experimental results show that the composition can obviously reduce the content of dihydrotestosterone, estradiol, testosterone, gonadotropin-releasing hormone, and rat luteinizing hormone in the prostate serum of a model mouse, and increase the content of follicle-stimulating hormone. The above results show that the traditional Chinese medicine composition can inhibit sex hormone disorder, and has the effect of treating prostatic hyperplasia.

The present invention pertains in general to the field of the stabilization of gonadotropin formulations, in particular liquid formulations of gonadotropins. The stabilization is achieved by a particular combination of excipients, preferably arginine and methionine. In a preferred embodiment, the formulation does not comprise a buffer.